BioCentury | Aug 17, 2017
Finance

Built to purpose

...cap Aires Pharmaceuticals Inc. Novartis AG MPM Capital Cardiovascular Single target 2010 2014 Acquired by Mast Therapeutics Inc....
BioCentury | Mar 17, 2017
Clinical News

AIR001: Ph I/II started

...I/II trial to evaluate AIR001. Mast will provide the compound and nebulizers for the study. Mast Therapeutics Inc....
...lung function, exhaled airway nitric oxide and bacterial density Status: Phase I/II started Milestone: NA Nora Weintraub AIR001 Aironite Mast Therapeutics Inc....
BioCentury | Mar 15, 2017
Company News

Mast, University of Pittsburgh deal

...sodium nitrite. Mast Therapeutics Inc. (NYSE-M:MSTX), San Diego, Calif. University of Pittsburgh , Pittsburgh, Pa. Business: Infectious Nora Weintraub AIR001 Mast Therapeutics Inc. University...
BioCentury | Dec 30, 2016
Clinical News

AIR001: Ph II INABLE-TRAINING started

...12 weeks in about 68 patients undergoing exercise training as part of standard cardiac rehab. Mast Therapeutics Inc....
...quality of life (QOL) and symptoms of heart failure Status: Phase II started Milestone: NA Julian Zhu AIR001 Aironite Mast Therapeutics Inc....
BioCentury | Oct 3, 2016
Finance

Dressed in black

...annual cash expenses by about $3M. Imprimis produces and markets compounded formulations of drugs. 9/26/16 Mast Therapeutics Inc....
BioCentury | Oct 3, 2016
Company News

Mast Therapeutics cardiovascular, hematology news

...30, the company had a six-month operating loss of $21 million (see BioCentury, Sept. 26). Mast Therapeutics Inc....
BioCentury | Sep 26, 2016
Clinical News

Vepoloxamer: Phase III data

...100 mg/kg vepoloxamer for 1 hour followed by a 30 mg/kg/hour dose for 12-48 hours. Mast Therapeutics Inc....
BioCentury | Aug 8, 2016
Clinical News

Aironite: Phase II started

...evaluate thrice-daily AIR001 in about 100 heart failure patients ages >40 with preserved ejection fraction. Mast Therapeutics Inc....
BioCentury | Apr 4, 2016
Finance

2Q milestones

...6/28/16 Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) Ganaxolone (CCD-1042) Drug-resistant focal onset seizures Ph III data Mid-2016 Mast Therapeutics Inc....
BioCentury | Apr 4, 2016
Finance

Fundamental reset

...2/19/16 $6.3 NA $23.4 NA Spectral Medical Inc. (TSX:EDT; OTCQX:EDTXF) 2/18/16 $7.6 $105.0 $116.7 11% Mast Therapeutics Inc....
Items per page:
1 - 10 of 199
BioCentury | Aug 17, 2017
Finance

Built to purpose

...cap Aires Pharmaceuticals Inc. Novartis AG MPM Capital Cardiovascular Single target 2010 2014 Acquired by Mast Therapeutics Inc....
BioCentury | Mar 17, 2017
Clinical News

AIR001: Ph I/II started

...I/II trial to evaluate AIR001. Mast will provide the compound and nebulizers for the study. Mast Therapeutics Inc....
...lung function, exhaled airway nitric oxide and bacterial density Status: Phase I/II started Milestone: NA Nora Weintraub AIR001 Aironite Mast Therapeutics Inc....
BioCentury | Mar 15, 2017
Company News

Mast, University of Pittsburgh deal

...sodium nitrite. Mast Therapeutics Inc. (NYSE-M:MSTX), San Diego, Calif. University of Pittsburgh , Pittsburgh, Pa. Business: Infectious Nora Weintraub AIR001 Mast Therapeutics Inc. University...
BioCentury | Dec 30, 2016
Clinical News

AIR001: Ph II INABLE-TRAINING started

...12 weeks in about 68 patients undergoing exercise training as part of standard cardiac rehab. Mast Therapeutics Inc....
...quality of life (QOL) and symptoms of heart failure Status: Phase II started Milestone: NA Julian Zhu AIR001 Aironite Mast Therapeutics Inc....
BioCentury | Oct 3, 2016
Finance

Dressed in black

...annual cash expenses by about $3M. Imprimis produces and markets compounded formulations of drugs. 9/26/16 Mast Therapeutics Inc....
BioCentury | Oct 3, 2016
Company News

Mast Therapeutics cardiovascular, hematology news

...30, the company had a six-month operating loss of $21 million (see BioCentury, Sept. 26). Mast Therapeutics Inc....
BioCentury | Sep 26, 2016
Clinical News

Vepoloxamer: Phase III data

...100 mg/kg vepoloxamer for 1 hour followed by a 30 mg/kg/hour dose for 12-48 hours. Mast Therapeutics Inc....
BioCentury | Aug 8, 2016
Clinical News

Aironite: Phase II started

...evaluate thrice-daily AIR001 in about 100 heart failure patients ages >40 with preserved ejection fraction. Mast Therapeutics Inc....
BioCentury | Apr 4, 2016
Finance

2Q milestones

...6/28/16 Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) Ganaxolone (CCD-1042) Drug-resistant focal onset seizures Ph III data Mid-2016 Mast Therapeutics Inc....
BioCentury | Apr 4, 2016
Finance

Fundamental reset

...2/19/16 $6.3 NA $23.4 NA Spectral Medical Inc. (TSX:EDT; OTCQX:EDTXF) 2/18/16 $7.6 $105.0 $116.7 11% Mast Therapeutics Inc....
Items per page:
1 - 10 of 199